News & Events
Andarix Pharmaceuticals to Present at Clinical Trials in Rare Diseases Conference 2022
Personalized and targeted medicine for rare lung and other cancers SOMERVILLE, MA —December 6, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its clinical strategy and results at the upcoming clinical trials in rare diseases conference. The Clinical Trials in Rare…
Read MoreAndarix Pharmaceuticals to Present Targeted Lung Cancer Technology at Clinical Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 12, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a clinical provider conference. The conference will focus on…
Read MoreAndarix Pharmaceuticals to Present Lung Cancer Therapy Technology at Clinical Trials Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —July 23, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a therapeutics conference. The conference will focus on a diversity…
Read MoreAndarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…
Read MoreAndarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
Targeted therapy for breast cancer is based on personalized medicine approach SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address…
Read MoreAndarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…
Read MoreAndarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 18, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the…
Read MoreAndarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
The Andarix drug addresses the growing Lung Cancer problem in Asia SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto,…
Read MoreAndarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29…
Read MoreAndarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…
Read More